Clinical Trials Logo

Filter by:
NCT ID: NCT05887726 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This study is a prospective, open-label, single-arm phase II clinical study to evaluate the safety and efficacy of zanubrutinib plus R-CHOP (ZR-CHOP) as the first-line therapy for newly diagnosed diffuse large B-cell lymphoma patients with high-risk factors.

NCT ID: NCT05885984 Not yet recruiting - Lung Cancer Clinical Trials

Acceptance and Commitment Therapy on Fatigue Interference in Patients With Advanced Lung Cancer and Caregiver Burden (ACT)

Start date: July 2023
Phase: N/A
Study type: Interventional

Lung cancer is a malignant tumour that has transformed from a single cancer disease into one of the most striking global health problems. Lung cancer has an insidious onset, and most patients are first diagnosed with the middle and advanced stages. Cancer-related fatigue is the most common and distressing symptom reported by lung cancer patients. For cancer patients, fatigue has a lasting impact on physical, psychological and social functions, and interferes with activities and participating in life events, thereby worsening the health-related quality of life. Family members have a key role in providing advanced lung cancer patients with informational, instrumental, and emotional support, which is crucial to patients' adaptation to the advanced illness and living a meaningful cancer life. Acceptance and Commitment Therapy (ACT) is the third-wave cognitive behavioural therapy to improve functioning and health-related quality of life by increasing psychological flexibility. The study aims to examine test the feasibility and acceptability, and preliminary effects of online ACT on fatigue interference in patients with advanced lung cancer and caregiver burden.

NCT ID: NCT05885919 Not yet recruiting - Clinical trials for Ischemic Stroke, Acute

Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke

EARLYS
Start date: July 1, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to evaluate the efficacy and safety of initiation of edaravone dextivel therapy compared with placebo in patients with acute ischaemic stroke (early and late) and to explore the optimal time window for "brain cell protective therapy" of edaravone dexborneol.

NCT ID: NCT05883774 Not yet recruiting - Clinical trials for Generalized Anxiety Disorder

Effects of rTMS on the Anxiety State of Older Patients With GAD

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effects of low-frequency repetitive transcranial magnetic stimulation on anxiety state in older patients with generalized anxiety disorder.

NCT ID: NCT05883709 Not yet recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

Start date: July 1, 2023
Phase:
Study type: Observational

To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.

NCT ID: NCT05883683 Not yet recruiting - Clinical trials for Recurrent Colorectal Carcinoma

Molecular Study and Precision Medicine for Colorectal Cancer

MSPM
Start date: July 1, 2023
Phase:
Study type: Observational

Researchers collect specimens from advanced or recurrent colorectal cancer (CRC) patients to conduct molecular profiling and establish tumor organoids (PDOs)/ patient-derived xenografts (PDXs). The aim of this study is to identify clinical actionable targets and predict in vivo response of the tumor to targeted drugs by using PDOs/ PDXs. And the above-mentioned studies will provide the patients with potential personalized cancer treatment options.

NCT ID: NCT05883592 Not yet recruiting - Aortic Dissection Clinical Trials

A Real-World Study on Distal Aortic Remodeling for Stanford Type B Aortic Dissection With Fabulous Thoracic Aortic Stent System

Start date: May 2023
Phase:
Study type: Observational

To evaluate aortic remodeling of Fabulous thoracic aortic stent system in the treatment of acute and subacute Stanford type B aortic dissection (the changes of aortic diameter, cross-sectional area,and volume of true lumen, false lumen and total aorta in different aoritc levels, and false lumen thrombosis in different aoritc levels), and splanchnic artery perfusion.

NCT ID: NCT05883176 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma by BCLC Stage

TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria

B-TACE
Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with anti-VEGF (Bevacizumab Biosimilar) in patients with BCLC-B stage hepatocellular carcinoma beyond up-to-seven criteria.

NCT ID: NCT05882630 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Start date: June 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluates the effectiveness and safety of Surufatinib combined with Serplulimab plus chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Surufatinib combined with Serplulimab

NCT ID: NCT05882487 Not yet recruiting - Parkinson Disease Clinical Trials

Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD

Start date: June 1, 2023
Phase: Early Phase 1
Study type: Interventional

This is a non-randomized, open label, dose-escalation study to evaluate the safety and efficacy of KL002 in the treatment of advanced primary Parkinson's disease. Condition or disease: Parkinson's Disease Intervention/treatment: Drug: KL002 Phase: NA